Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Work In Process (2021 - 2025)

Historic Work In Process for Mirum Pharmaceuticals (MIRM) over the last 5 years, with Q3 2025 value amounting to $18.3 million.

  • Mirum Pharmaceuticals' Work In Process rose 2838.41% to $18.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.3 million, marking a year-over-year increase of 2838.41%. This contributed to the annual value of $16.1 million for FY2024, which is 6295.96% up from last year.
  • According to the latest figures from Q3 2025, Mirum Pharmaceuticals' Work In Process is $18.3 million, which was up 2838.41% from $16.3 million recorded in Q2 2025.
  • Mirum Pharmaceuticals' Work In Process' 5-year high stood at $18.3 million during Q3 2025, with a 5-year trough of $553000.0 in Q1 2022.
  • In the last 5 years, Mirum Pharmaceuticals' Work In Process had a median value of $10.2 million in 2023 and averaged $9.7 million.
  • Per our database at Business Quant, Mirum Pharmaceuticals' Work In Process skyrocketed by 107251.36% in 2023 and then skyrocketed by 2838.41% in 2025.
  • Mirum Pharmaceuticals' Work In Process (Quarter) stood at $570000.0 in 2021, then surged by 838.77% to $5.4 million in 2022, then skyrocketed by 84.51% to $9.9 million in 2023, then soared by 62.96% to $16.1 million in 2024, then rose by 13.77% to $18.3 million in 2025.
  • Its Work In Process stands at $18.3 million for Q3 2025, versus $16.3 million for Q2 2025 and $15.8 million for Q1 2025.